Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial (Q34442510)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial |
scientific article |
Statements
1 reference
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial (English)
1 reference
Richard B Lipton
1 reference
Messoud Ashina
1 reference
Peter J Goadsby
1 reference
David W Dodick
1 reference
Stephen D Silberstein
1 reference
Kerri Wilks
1 reference
David Kudrow
1 reference
Robin Kroll
1 reference
Bruce Kohrman
1 reference
Robert Bargar
1 reference
Joe Hirman
1 reference
Jeff Smith
1 reference
ALD403 study investigators
1 reference
5 October 2014
1 reference
1 reference
13
1 reference
11
1 reference
1100-1107
1 reference
Identifiers
1 reference
1 reference